


AMC – First TPLA Protocol cases

Amsterdam | December 4, 2018

The Academic Medical Center (AMC) is the university hospital affiliated with the University of Amsterdam. It is one of the largest and leading hospitals of The Netherlands, ranking among the top 50 medical schools in the world.



Elesta is collaborating with AMC in a prospective, single centre, interventional pilot study entitled **Transperineal Laser Ablation for Treatment of Benign Prostatic Obstruction**: the aim of the study is to prove feasibility and safety of TPLA for LUTS due to BPO in healthy men and to determine functional voiding, erectile outcomes and changes on imaging. On December 4th 2018, thanks to the support of one of the pioneers of SoracteLite treatment, Dr. Gianluigi Patelli - Head of Radiology Dept. ASST Bergamo Est - the first three patients underwent SoracteLite procedure performed by Prof. Dr. Theo M. De Reijke: all the patients were treated with no complications and were dismissed few hours after the procedure.



September 7-10, 2019

Budapest Congress Center,
Budapest, Hungary

42nd Annual Meeting of the
European Thyroid Association

September 7-11, 2019

Centre Convencions Internacional de
Barcelona, Barcelona, Spain

Cardiovascular and Interventional
Radiological Society of Europe
(CIRSE) Congress – 2019

September 12, 2019

Hotel Metropole, Geneva, Switzerland

Prostate - Place of focal therapy in a
prostate cancer treatment platform

October 12-15, 2019

Palazzo del Casinò, Venice, Italy

Società Italiana di Urologia (SIU)
Congress

November 7-10, 2019

Ergife Palace Hotel, Rome, Italy

18thAME National Congress

November 15-16, 2019

Centro Palmer, Reggio Emilia, Italy


1st International Meeting on
Ultrasound Assisted Thyroid
Minimally Invasive Therapies

SoractelLite educational trip in China

China | December 5-10, 2018

In 2017 Elesta organized the first educational trip focused on SoractelLite procedure: with the support of Dr. Gianluigi Patelli, the Italian pioneer of the procedure, the treatment was introduced with theoretical presentations and live procedures performed in some of the most important Chinese hospitals. It was a great experience and the innovative technique aroused great interest in the participants, resulting in the application of SoractelLite as a clinical alternative for the management of Chinese patients affected by Benign Prostatic Hyperplasia (BPH).

From that date, SoractelLite is spreading rapidly in Italy and abroad, with a growing number of doctors learning the technique and importing it into other hospitals.



In December 2018 the second educational trip to China was performed in collaboration with Dr. Gennaro Iapicca, KOL on the procedure, who introduced last clinical updates and applications of the procedure, focusing on SoractelLite performances for the treatment of low-risk, localised malignant lesions of the prostate.



Trattamenti percutanei nella patologia tiroidea


Milan | February 7-8, 2019

The second edition of the Italian Conference on Thyroid Minimally Invasive Treatments was held in Milan, Italy, on February 7th – 8th 2019.

With more than 130 multidisciplinary participants and 20 faculty members with specific expertise in the field of thyroid disease, the event, organised by the Italian Research Group for Thyroid Minimally Invasive Treatment (IRGT-MIT), represents the largest meeting fully dedicated to an appraisal of the role of minimally invasive treatments for thyroid lesions. During the Conference, Professor Enrico Papini presented the "Italian Consensus on MIT": a list of statements based on literature review and consensus opinion of interdisciplinary experts to facilitate the diffusion and the appropriate use of MIT of thyroid nodules in clinical practice. The Consensus was then published on International Journal of Hyperthermia in March 2019:

Minimally-invasive treatments for benign thyroid nodules: a Delphi-based consensus statement from the Italian minimally-invasive treatments of the thyroid (MITT) group.

Papini E et al., Int J Hyperthermia. 2019;36(1):376-382.



Elesta took part to the conference presenting EchoLaser system through practical sessions during which participants could experience the mode of action of the system.

SoracteLite clinical updates presented at ECR 2019

Vienna | February 28, 2019

Outcome in 73 patients with benign prostatic hyperplasia treated by an ultrasound guided transperineal laser ablation by interventional radiologists

G. Patelli¹, F. Besana¹, E. Faietti¹, G. Ori Belometti¹, C. Costa¹, A. D'Alessio², G. Mauri³, C. M. Pacella⁴;

¹Seriata/IT; ²Zingonia/IT; ³Milan/IT; ⁴Rome/IT

Abstract

Purpose

To report results of ultrasound-guided (US-g) Transperineal Laser Ablation (TPLA) in patients with Benign Prostatic Hyperplasia (BPH).

Methods and Materials

Seventy-three patients (mean age 72.6±10.4years, range 58-93) with obstructive syndrome secondary to BPH, were treated by TPLA using continuous wave (CW) diode laser source at 1064nm (EchoLaser SoracteLite, Elesta s.r.l., Calenzano (FI), Italy). Under transrectal US-g, one or two 21G introducer needles for each

lobe, according to the prostate volume, were inserted with transperineal approach.


Each ablation was performed at 3W power for 1800J energy. A pull back was done case by case according to the prostate volume. Major and minor complications were recorded. The efficacy was evaluated on the changes of means of International Prostate Symptoms Score (IPSS), Quality of Life (QoL), post-void residual (PVR), prostate volume and the ejaculatory function. The mean hospital stay was measured.

Results

At a mean follow-up time of 16 months (range 3-45), IPSS improved from 22.9 to 9.6 (P<0.001), QoL from 4.5 to 1.2 (P<0.001), PVR from 162.3 ml to 64 ml (P<0.001) and prostate volume from 73.47 ml to 50.8 ml (P<0.001). Of 34 patient evaluated for ejaculatory function, 32 (94%) maintained a satisfactory ejaculation. No major complications occurred. The mean operation time was 42.3±8.7min, ablation time 15.6±3.4min, energy deployed 11,540.0±3,680.5J, hospital stay 1.7±0.4days.

Conclusion


TPLA is a mini invasive treatment for BPH. This therapeutic approach was safe, efficacious and with a satisfactory outcome.



GVM Care & Research - Scientific Conference on EchoLaser Therapies

Bari | March 1-2, 2019

Thanks to the cooperation between Elesta and GVM Care & Research network, the scientific conference on EchoLaser Therapies was organized. The first day has seen the D'Amore Hospital, which is part of the network GVM, hosting the first intervention among GVM hospitals with ModiLite EchoLaser Therapy, performed by Prof. Pier Paolo De Feo and Dr. Giovanni Gambelunghe from Delta Implants Clinic from Liotti Clinic, Perugia.



On the second day, the scientific conference organized by Dr. Alfredo Procaccini - responsible for thyroid surgery at the D'Amore Hospital in Taranto - consisted of theoretical lectures followed by real case presentations held by Italian KOLs on EchoLaser Therapies: Prof. Pier Paolo De Feo and Dr. Giovanni Gambelunghe introduced ModiLite for the treatment of neck lesions, Dr. Gianluigi Patelli - Head of Radiology Dept., ASST Bergamo Est - presented SoracteLite treatment for treating benign and malignant urological pathologies, while Dr. Giovan Giuseppe Di Costanzo - Head of Epatology Dept., Cardarelli Hospital, Naples - exposed PBLite application for the treatment of malignant abdominal tumours.

SoracteLite Workshop – EAU Congress 2019

Barcelona | March 14th – 19th, 2019

Despite first SoracteLite procedures were addressed only to benign pathologies (BPH), it has recently been applied with clinical success also to the treatment of Prostate Cancer (PCa).

During the workshop held in Barcelona just before the European Association of Urology Congress, SoracteLite KOLs from Italy and abroad presented up-to-date clinical results on both benign and malignant applications.

Dr. Gennaro Iapicca (Santa Rita Clinic, Italy) and Prof. T.M. De Reijke (AMC, Amsterdam) focused on benign applications presenting the procedure and the multicentre international registry, an international prospective observational study to evaluate SoracteLite treatment in terms of long-term efficacy, functional outcomes and safety.

Prof. Guglielmo Manenti (Policlinico Tor Vergata, Rome) and Dr. Stefano Regusci (SIPC, Geneva) presented last updates on the malignant application for the treatment of patients with localized and low/intermediate-risk prostate tumor.



The event arouses great interest with more than 30 attendees from all over Europe, who were positively impressed from the innovations, clinical results and future perspectives of the procedure.

Elasta took part also to the Annual EAU Congress, Europe's biggest urological event with specialists and affiliated medical professionals gathering for a critical assessment of clinical practices and key research developments.



The congress presented the latest improvements in science and education in various formats to suit the needs of all participants, including challenging state-of-the-art lectures, fascinating HD live video sessions, skill-boosting hands-on training and practice-oriented courses.



Thermal Ablative Techniques, International Symposium

Belgrade | March 25, 2019

The symposium organized by Prof. Dr. Dragan Mašulović took place in the Radiology and MRI Clinical Center of Belgrade, Serbia. The aim of the symposium was to increase the awareness of thermal ablative technologies in Serbia and to present EchoLaser Therapy as a new and additional treatment modality for patients in Serbia. Two Italian KOLs on EchoLaser Therapy, Dr. Di Costanzo (Cardarelli Hospital, Naples) and Dr. Esposito (Casa di Cura La Madonnina, Cosenza), had lectures on technology and liver application and on prostate and thyroid applications respectively. Both presenters doctors gave presentations based on available literature and presented their own experience and some case studies. Live clinical cases were performed after theoretical presentation and live streamed to the auditorium.



The symposium was attended by over 75 doctors and it had CME credit points awarded by Medical Chamber of Serbia. The participants were also officially welcomed by Secretary of Ministry of Health. Prof. Mašulović was also interviewed by local TV and reported his satisfaction about the procedures.



Registered clinical trials and publications on EchoLaser Therapies

Registered clinical trials

SoracteLite

Registry of Transperineal Laser Ablation for Treatment of Lower Urinary Tract Symptoms With Use of the EchoLaser® Device: A Multicentre, International Registry to Evaluate the Treatment of LUTS in Terms of Long-term Efficacy, Functional Outcomes and Safety

Principal Investigator Academisch Medisch Centrum, Amsterdam

Clinicaltrial.gov link <https://clinicaltrials.gov/ct2/show/NCT03776006>

Transperineal Laser Ablation for Treatment of LUTS Due to Benign Prostatic Obstruction

Principal Investigator Academisch Medisch Centrum, Amsterdam

Clinicaltrial.gov link <https://clinicaltrials.gov/ct2/show/NCT03653117>

Pancreas

EUS-guided Laser Ablation of Advanced Pancreatic Ductal Adenocarcinoma: a Feasibility Study

Principal Investigator Catholic University of the Sacred Heart, Rome

Clinicaltrial.gov link <https://clinicaltrials.gov/ct2/show/NCT03784417>

New publications

ModiLite

Minimally-invasive treatments for benign thyroid nodules: a Delphi-based consensus statement from the Italian minimally-invasive treatments of the thyroid (MITT) group.

Papini E et al.

Int J Hyperthermia. 2019;36(1):376-382.

Ultrasound-guided percutaneous laser ablation for papillary thyroid microcarcinoma: a retrospective analysis of 37 patients.

Ji L, Wu Q, Gu J, Deng X, Zhou W, Fan X, Zhou F.

Cancer Imaging. 2019 Mar 20;19(1):16

Percutaneous ultrasound-guided laser ablation for the treatment of cervical tuberculous lymphadenitis: a pilot study.

Yang G, Fang J, Yu T, Zhang Y, Zhang W, Zhao D, Xu J, Wang C.

J Int Med Res. 2019 Jan 11:300060518821818.

Quality of life and outcomes in patients with a large toxic adenoma undergoing laser ablation plus radioiodine vs lobectomy.

Negro R, Greco G.

Int J Hyperthermia. 2018 Dec 16:1-5.

Percutaneous laser ablation for benign and malignant thyroid diseases.

Mauri G, Nicosia L, Della Vigna P, Varano GM, Maiettini D, Bonomo G, Giuliano G, Orsi F, Solbiati L, De Fiori E, Papini E, Pacella CM, Sconfienza LM.

Ultrasonography. 2018 Sep 17.

Year 2019
Edition n.3
July

EchoLaser news are available at
<http://www.elesta-echolaser.com/echolaser-magazine/>

EchoLaser Club/contacts
Tel +39 055 8826807
Fax +39 055 7766698
e-mail info@elesta-echolaser.com

ModiLite
<http://modilite.info>

SoracteLite
<http://soractelite.info>

ELESTA
Beyond Laser

Elesta s.r.l.
Via Baldanzese 17 50041 Calenzano, Italy
Tel. +39 055 8826807 Fax +39 055 7766698
www.elesta-echolaser.com

EchoLaser News and any files transmitted with it are confidential. The EchoLaser members are authorized to view and make a single copy of parts of its content for offline, personal, non-commercial use. The content may not be sold, reproduced, or distributed without our written permission. Any third-party trademarks, service marks and logos are the property of their respective owners. Any further rights not specifically granted herein are reserved.

We are pleased to announce the update of our patient websites www.modilite.info and www.soractelite.info.

Completely renewed in their graphics and contents, the websites reports information on the pathologies and treatments with EchoLaser.

